Document:

exv4w5xay

Exhibit 4.5A

THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY

Fluidigm Corporation

a California corporation

CONVERTIBLE PROMISSORY NOTE

NOTE NUMBER E-3 (REVISED)

			
	 	 	 
	US$5,000,000
	 	April 19, 2007
	 
	 	South San Francisco, California

     1. Principal and Interest. Fluidigm Corporation (the “Company”), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the “Holder”) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365 days, compounded annually.

     This Convertible Promissory Note (“Note”) is the third Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August 7, 2006 (as amended, modified or
supplemented, the “Note Purchase Agreement”) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.

     Unless converted in accordance with Section 3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section 3). This Note may
be prepaid by Company at any time, in accordance with the terms of Section 2 of this Note. Upon
payment in full of all principal and interest payable hereunder (including upon any conversion),
this Note shall be surrendered to the Company for cancellation. All payments hereon shall be
applied first to accrued interest and second to the reduction of principal.

 

 

     2. Prepayment of Note. Upon five days prior written notice to Holder (the
“Prepayment Notice”), the Company may prepay this Note in whole or in part; provided that
any such prepayment will be applied first to the payment of expenses due under this Note, second to
interest accrued on this Note and third, if the amount of prepayment exceeds the amount of all such
expenses and accrued interest, to the payment of principal of this Note. In the event that the
Holder desires to avoid prepayment of the Note by the Company, the Holder must within five days of
its receipt of the Prepayment Notice deliver to the Company the Conversion Notice pursuant to
Section 3(c)(iii) electing to convert this Note, in which case this Note will not be prepaid as
provided in the Prepayment Notice and will instead be converted into shares of Series E Preferred
Stock of the Company in accordance with Section 3 of this Note.

     3. Conversion.

          (a) Conversion Events. Upon the earlier to occur of (i) an Initial Public Offering
(as defined below) or (ii) satisfaction of each of the Milestones pursuant to Section 3(b)(iv)
below (either, a “Conversion Event”), all of the then outstanding principal and accrued
interest owing under this Note shall convert into that number of shares of Series E Preferred Stock
of the Company determined by dividing (i) the aggregate principal and accrued interest owing under
this Note as of the date of such Conversion Event by (ii) the Conversion Price (as defined below).
Notwithstanding the foregoing, by complying with Section 3(c)(iii) hereof, the Holder may at any
time earlier elect to convert this Note into that number of shares of Series E Preferred Stock
determined by dividing (i) the aggregate principal and accrued interest owing under this Note as of
the date of the Conversion Notice (as defined in Section 3(c)(iii)) by (ii) the Conversion Price
(as defined below).

          (b) Definitions. For purposes of this Note, the following terms shall have the
following meanings:

               (i) The term “Change of Control Transaction” shall mean (i) the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii) a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.

               (ii) The term “Conversion Price” shall mean US$3.60, subject to adjustment as set
forth in Section 5 below.

               (iii) The term “Initial Public Offering” shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
“Securities Act”) after or in connection with which the outstanding shares of Preferred
Stock of the

 

 

Company have been converted into Common Stock pursuant to the Company’s then existing Articles
of Incorporation or otherwise.

               (iv) Unless otherwise agreed in writing between the Company and the Holder, the term
“Milestones” shall mean satisfaction of the following on or before April 30, 2008:

                    (1) The
Company will have released the BioMark II Chip Loader to
manufacturing, as
demonstrated by a Manufacturing Release approval form duly signed-off. The approval is typically
characterized by having completed standard prototype development,
including building and testing of
suitable prototypes;

                    (2) The
approved BioMark II Chip Loader (or a subsequent version thereof)
will be made
generally available to customers, as demonstrated by a Company
product announcement;

                    (3) The
Subsidiary will also have
produced prototype BioMark II End Point Readers and made
them available to at least three (3) customers;

                    (4) The
Subsidiary will have at least maintained the number of Research and Development
Engineers hired to achieve Milestones in the First Note and the
Milestones in the Second Note; and

                    (5) The
Company will be manufacturing the BioMark II Chip Loader through the Subsidiary in
Singapore, and the Company’s then-current financial and
business plan will provide for the
manufacturing of the BioMark II End Point Readers through the
Subsidiary in Singapore; provided
that if the Holder provides the Company with a
Milestone Response Notice pursuant to Section
3(c)(ii) below, then the Company shall have 30 days following the Company’s receipt of the
Milestone Response Notice (the “Milestones Cure
Period”) to cure any failure to satisfy the
Milestones identified by the Holder in the
Milestone Response Notice.

               (v) The term “Payment Date” shall mean April 19, 2009 or such later date as may be
mutually agreed in writing by Holder and the Company.

          (c) Conversion Procedure.

               (i) Conversion in Connection with Initial Public Offering. Upon the occurrence of an
Initial Public Offering as set forth in Section 3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.

               (ii) Conversion in Connection with Satisfaction of Milestones. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the “Milestone Completion Notice”) to the Holder (at the address last shown on the records

 

 

of the Company for the Holder or given by Holder to Company for the purpose of notice)
specifying the Conversion Price, the date on which the Company reasonably believes all of the
Milestones were satisfied (the “Notified Milestone Completion Date”), together with a duly
executed compliance certificate dated as of the Notified Milestone Completion Date substantially in
the form attached hereto as Exhibit A (the “Compliance Certificate”), and calling
upon Holder to surrender to the Company the Note. In the event that the Holder reasonably believes
that any of (i) the Milestones have not been satisfied or (ii) the representations and warranties
made in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the “Milestone Response Notice”) to the Company of such disagreement and/or
inaccuracy within 30 days of its receipt of the Milestone Completion Notice. The Milestone
Response Notice shall specify in reasonable detail the reasons for such disagreement and/or basis
for belief that any of the representations and warranties made in the Compliance Certificate are
inaccurate and shall be accompanied by reasonably available support documentation evidencing the
basis for such disagreement or belief. If the Holder shall fail to provide the Milestone Response
Notice within such time period, the Milestones shall be deemed satisfied as of the Notified
Milestone Completion Date and this Note shall be automatically converted as set forth in
Section 3(a). If the Holder shall have timely provided the Milestone Response Notice, the Company
and the Holder shall in good faith attempt to resolve their disagreement as to the satisfaction of
the Milestones and/or the accuracy of the representations and warranties in the Compliance
Certificate. If the Company and Holder are unable to resolve their disagreement within the
Milestones Cure Period, the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.

               (iii) Elective Conversion. If the Holder wishes to voluntarily convert this Note as
set forth in Section 3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the “Conversion Notice”) to
that effect.

               (iv) Certificate; Time of Conversion. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section 3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section 3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section 3(c)(iii), upon the Company’s receipt of
such Conversion Notice); provided, however, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.

 

 

          (d) Fractional Shares. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.

          (e) Reservation of Shares. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series E
Preferred Stock or other securities to permit the full conversion of the outstanding principal and
interest of this Note pursuant to the terms of this Note. In the event the Company shall have
insufficient shares of Series E Preferred Stock or other securities to permit the full conversion
of the outstanding principal and accrued interest of this Note pursuant to the terms hereof, the
Company hereby covenants and agrees that the Company shall use its commercially reasonable efforts
to seek board and shareholder approval of an amendment to the Company’s Articles of Incorporation
in order to authorize an increase in the number of authorized shares of Series E Preferred Stock or
other securities of the Company in a sufficient amount so that the aggregate number of shares of
Series E Preferred Stock or other securities issuable upon conversion of this Note will then be
authorized and available for issuance.

     4. Change of Control Transaction. The Company shall provide the Holder with 15 days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section 3(c)(iii) within such 15 day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.

     5. Change in Series E Preferred Stock.

          (a) Split, Subdivision or Combination of Series E Preferred Stock. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such

 

 

decrease in outstanding shares of Series E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable.

          (b) Reclassification etc. In case of any reclassification, capital reorganization, or
change in the Series E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company’s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section 5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
that this Note shall be convertible upon the terms set forth herein into the kind and amount of
shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series E
Preferred Stock or other securities as are issuable on conversion of this Note.

          (c) Merger or Consolidation. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.

     6. Payment Due Date. If not previously converted into shares of Series E Preferred
Stock pursuant to Section 3 hereof and if not sooner prepaid by the Company pursuant to Section 2
hereof or accelerated and declared due and owing by the Holder pursuant to Section 7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.

     7. Default. The Company shall be deemed to be in default under this Note in the event
(i) the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section 4 of the Note Purchase Agreement for a period of 30 days after written notice of such
failure from Holder; (ii) the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii) the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,

 

 

demand, protest, or further notice of any kind, as well as enforce all other rights and
remedies available to the Holder under applicable law.

     8. Notices. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:

	 	 	 	 	 
	 
	 	If to Holder:	 	Biomedical Sciences Investment Fund Pte Ltd
	 
	 	 	 	20 Biopolis Way
	 
	 	 	 	#09-01 Centros
	 
	 	 	 	Singapore 138668
	 
	 	 	 	Attention: Chu Swee Yeok
	 
	 	 	 	Tel:  65-6336-2288
	 
	 	 	 	Fax:  65-6334-8478
	 
	 	 	 	 
	 
	 	If to the Company:	 	Fluidigm Corporation
	 
	 	 	 	7100 Shoreline Court
	 
	 	 	 	South San Francisco, California  94080
	 
	 	 	 	Attention:  Chief Executive Officer
	 
	 	 	 	Tel:  (650) 266-6000
	 
	 	 	 	Fax: (650) 871-7195
	 
	 	 	 	 
	 
	 	 	 	with a copy to:
	 
	 	 	 	 
	 
	 	 	 	Wilson Sonsini Goodrich & Rosati, P.C.
	 
	 	 	 	650 Page Mill Road
	 
	 	 	 	Palo Alto, California  94304-1050
	 
	 	 	 	Attention:  Ken Clark and Robert Kornegay
	 
	 	 	 	Tel: (650) 493-9300
	 
	 	 	 	Fax: (650) 493-6811

     Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.

     9. Amendments. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.

     10. No Rights as Shareholder. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.

 

 

     11. Successors and Assigns. Subject to the restrictions on transfer described in
Section 12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.

     12. Transfer of Note and Securities Issuable on Conversion Hereof. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
transfer, pledge or other disposition of the securities into which this Note may be converted after
conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June 13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the “Rights Agreement”). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections 1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.

     13. Highest Lawful Rate. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, “Highest Lawful Rate” means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.

     14. Miscellaneous. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys’ fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder’s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to “dollars” or “$” in this Note shall refer to the lawful
money of the United States of America.

 

 

     IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.

	 	 	 	 	 	 	 
	Dated: April 19, 2007	 	Fluidigm Corporation	 	 
	 	 	a California corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Gajus V. Worthington
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Gajus Worthington
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Chief Executive Officer
 

	 	 
	 
	 	 	 	 	 	 
	Acknowledged and Agreed:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Holder	 	 
	 
	 	 	 	 	 	 
	 	 	Biomedical Sciences Investment Fund Pte Ltd	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Chu Swee Yeok
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Chu Swee Yeok
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Directorexv10w8

[***] Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.

Exhibit 10.8

					
	 	 	 	 	 
	 
	 	PATENT LICENSE AGREEMENT
	 	3950.LICI.001 Gyros AB

This Agreement, effective as of January 9, 2003, is made by and between GYROS AB having its
principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and
existing under the laws of Sweden (hereinafter referred to as
“Licensor”), and FLUIDIGM Corporation
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation
organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as
the “Licensee”).

 

RECITALS

WHEREAS, the Licensor is the holder of intellectual property pertaining to, and possesses a special
expertise in the field of fluidic microsystems.

WHEREAS, the Licensor is active in the field of microfluidics and microfluidic applications,
primarily within the Life Sciences and Diagnostics.

WHEREAS, the Licensor is the owner of certain patents and patent applications pertaining to
microfluidics and microfluidic applications.

WHEREAS, Licensor is willing to grant Licensee a royalty-bearing non-exclusive licence to such
patents on the terms and conditions given below.

NOW, THEREFORE, in consideration of the promises and the faithful performance of the covenants
herein contained IT IS AGREED;

ARTICLE 1 DEFINITIONS

	1.1	 	“Affiliate” shall mean any corporation, partnership, or other business entity
controlled by, or controlling, or under common control with any party or signatory to this
Agreement, with “control” meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting power, or of the interest in the income of such corporation,
partnership or other entity, or having the power to appoint the majority of its directors or
otherwise having the power to direct its business activities.

1.2     “Competitor of Licensor” shall mean a company in the business of making and selling
compact disc-like structures in which fluids are moved by centrifugal force.

 

 

1.3 “Net Sales” shall mean the gross selling price charged by Licensee for Products
manufactured or sold by the Licensee in a country in which the Product is covered by a Patent
(i.e., a country in which, but for the license granted herein, the Product would infringe a valid,
enforceable, unexpired claim of a Patent) less:

	 	(a)	 	allowances for damaged and returned goods;
	 
	 	(b)	 	discounts actually credited to customers or commissions paid to third parties in amounts
customary in the trade;
	 
	 	(c)	 	custom duties, forwarding insurance premiums, sales, excise, and other taxes actually paid by
the Licensee or otherwise included in the gross selling price with respect to the sale of Products;

A Product shall be considered sold hereunder in accordance with extant GAAP accounting procedures
and guidelines.

If the Products are sold in combination with, or as a component of, other products not licensed
hereunder, Net Sales for purposes of determining royalty hereunder shall be calculated by
multiplying the Net Sales from the combined product by the fraction
A/B, where A is the invoice price of the Products sold separately and B is the invoice price of the
combined product. If the Products are not sold separately, the Net Sales for purposes of
calculating royalties hereunder shall be reasonably determined by agreement of Licensor and the
Licensee promptly after such combination products are sold by Licensee. The parties agree to use
good faith in negotiating the appropriate adjustment to Net Sales of any combined product within
thirty (30) days after the Licensee notifies Licensor of sales of a combination product. The Net
Sales of any Products sold by the Licensee to any Affiliate of the Licensee or any other person or
organization enjoying a special course of dealing with the Licensee, shall be determined by
reference to the Net Sales which would be applicable under this Article 1.2 in an arm’s length sale
of such Products by the Licensee to a third party.

1.4 “Patents” shall mean the patents listed in Exhibit A, attached hereto, together with
any other corresponding patents/ patent applications in any country owned or controlled by the
Licensor.

1.5 “Covered Products” shall mean all products now or hereafter manufactured, assembled, used
or sold by or on behalf of the Licensee or its Affiliates and which are covered by any of the
Patents.

It is hereby acknowledged that any and all products consisting of compact discs (“CD’s”) and
CD-like structures where a centrifugal force is utilized to move the liquids within the CD are
explicitly excluded from this definition.

	1.6	“Option Field of Use” means each of (i) [***] and (ii) [***].

 

 

	 	 	“Licensed Fields of Use” means [***] and each Option Field of Use for which
Licensee exercises the option as set forth in Section 5.2 below.
	 
	1.8	 	“Product” means each Covered Product useful, used, or for use in a Licensed Field of Use.

ARTICLE 2 GRANT

2.1 Upon the terms and subject to the conditions of this Agreement, Licensor hereby grants
to the Licensee and its Affiliates, and the Licensee and its Affiliates accept from Licensor, a
restricted, perpetual, irrevocable (except as set forth in
Section 9.1), non-exclusive,
non-transferable (except as set forth in Section 7.4), royalty-bearing license under the Patents
for the term hereof solely to make, have made, import, use, offer for sale, and sell Products. No
other license is granted to the Licensee expressly, impliedly or by estoppel, except as explicitly
set forth in Section 5.2 below.

	 	 	The Licensee expressly acknowledges and agrees that the Licensee shall have no right to sublicense,
assign, or otherwise transfer any or all of the license granted to it under the Patents, except as
set forth in Section 9.1, provided that Licensee can sublicense Patents to a third party other than
a Competitor of Licensor (as defined in Section 7.4) in conjunction with a license from Licensee to
make and sell any of Licensee’s Products. Licensor reserves the right to practice the Patents
itself, and to sublicense, assign or otherwise transfer the Patents to others for any purposes
whatsoever, provided that such transfer or assignment shall be subject to the licenses granted to
Licensee in this Agreement.
	 
	2.3	 	Licensor hereby irrevocably releases Licensee and its Affiliates, and each of their
subcontract manufactures and direct and indirect customers, of and from all claims of infringement
of Patents, known or unknown, which claims have been made or might have
been made at any time, with respect to any apparatus made, used, imported, offered for sale, or
sold, or any method or process practiced, before the effective date of this Agreement, which
apparatus, method, or process would have been licensed had it been made, used, imported, offered
for sale, or sold, or practiced after effective date of this Agreement. A corresponding release
will be deemed made in relation to each of the Option Fields of Use when and if exercised under
Section 5.2 below.

ARTICLE 3 PATENT MARKING

Beginning two (2) years after the effective date of this Agreement, Licensee shall display or cause
to be displayed proper patent notices on the documentation, inserts, packages or containers of all
Products which shall indicate that the Product is sold or manufactured under a patent license from
Licensor. The Licensee shall provide Licensor for its review prior to use,

 

 

representative samples containing such patent notices and the parties agree to use good faith in
determining the requirements for and adequacy of such notices under the controlling patent laws.

ARTICLE 4 RESTRICTIONS ON PUBLICATION

Upon the signing of this Agreement and upon exercise of any of the Option Fields of Use under 5.2,
both parties shall be entitled to make public — through a press
release or otherwise - that Licensee
has taken a license to the Patents from the Licensor. Such press-release or similar shall be in a
form reasonably acceptable to the other party and shall not disclose any of the financial terms
agreed in this Agreement. Within thirty (30) days of the effective date of this Agreement, Licensee
will publish on its corporate website that it has taken a license from Licensor under the Patents.
Under all other circumstances, neither party shall use the other’s name nor any variation thereof,
nor any emblem, logo, trademark or variation thereof, nor the name of any employee in any press
releases, advertising, promotional or sales literature, or in any securities reports required by
the Securities and Exchange Commission, without the prior written consent of the other party in
each case; provided however, that both parties (a) may refer to publications by employees of the
other party in the scientific literature, (b) may only state that a non-exclusive, royalty-bearing
patent license from Licensor to Licensee has been granted (excluding financial terms) and (c) may
make such disclosures as required by law.

ARTICLE 5 ROYALTIES AND PAYMENT

5.1 In consideration of the rights granted by Licensor to the Licensee under this Agreement, the
Licensee agrees to pay to Licensor:

	 	(a)	 	a non-refundable sum of [***] payable on March 31,
2003 (“Annual Payment Date”). The foregoing payment includes full payment for all sales by the
Licensee of Products before the effective date of this Agreement;
	 
	 	(b)	 	a sum of [***] payable on each anniversary of the
Annual Payment Date during the term of this Agreement; and
	 
	 	(c)	 	a royalty of [***] of the Net Sales of all Products sold by the Licensee during the
term of this Agreement. Sums paid under Subsections 5.1 (a) and (b) above, and Section 5.2 below,
shall be fully creditable against such royalties, regardless of the year in which such royalties
accrue.

5.2 At any time(s) during the first twelve (12) months of the term of this Agreement, Licensee
shall be entitled, at its option, to add one or both Option Fields of Use to the
Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field of
Use shall become a Licensed Field of Use under this Agreement. If Licensee has not, during the
first

 

 

twelve (12) month period of the term of this Agreement, added both Option Fields of Use to the
Licensed Field of Use, then during the second twelve (12) month period of the term of this
Agreement, Licensee shall be entitled, at its option, to add one Option Field of Use to the
Licensed Field of Use under this Agreement. Each such exercise of this option by Licensee shall be
by written notice to Licensor, referencing this Agreement and specifying the Option Field(s) of Use
to be added. Within thirty (30) days after such exercise, Licensee shall pay an additional
[***] license fee for the first added Option Field of Use, and an additional [***]
license fee for the second added Option Field of Use. For the avoidance of doubt, during the first
twelve (12) month period of the term of this Agreement, Licensee may exercise this option for one
or both Option Fields of Use and on one or two occasions.

5.3 Within thirty (30) days of the end of each calendar quarter the Licensee shall pay to Licensor
the royalty having accrued on the Products sold during such calendar quarter to the extent the
royalty exceeds the credited sums paid by Licensee. Such payments shall be made in US Dollars by
wire transfer, at the Licensee’s cost, to such bank as shall be notified by Licensor. Payments of
royalties accrued on sales in other currencies than US Dollars shall be made in US Dollars at the
rate of exchange quoted by a first class commercial bank in the Licensee’s country on the last day
of the relevant calendar quarter.

5.4 If the Licensee fails to make the payments as provided for herein, such amounts shall bear
interest from and after the due date at the rate of [***] above the one month LIBOR
for the currency of payment.

5.5 Withholding or other taxes assessed on Licensor in connection with the payment of royalties
and other consideration due hereunder and which the Licensee is required by law to deduct and
withhold when making payments, may be deducted from royalty payments hereunder (including without
limitation payments under Sections 5.1(a), 5.1(b), and 5.2) and shall be paid by the Licensee to
the competent authority on behalf of Licensor. The originals of the official government receipt for
such taxes paid by the Licensee on Licensor’s behalf, shall so indicate such fact and shall be sent
by the Licensee to Licensor not later than fifteen (15) working days after the date of payment,
indicating net payment of royalties to which such taxes relate, and in accordance with the
instructions given by Licensor. The sums so paid by the Licensee shall be credited by Licensor in
partial discharge of the Licensee’s obligation for gross royalties as provided for herein.

ARTICLE 6 RECORDS, AUDITS AND REPORTS

6.1 The Licensee agrees to maintain accurate, complete and up to date records, until five (5)
years after a royalty payment has been made, in sufficient detail to enable the royalties payable
by the Licensee to be determined. Licensor shall have the right, at its own expense and during
regular business hours, at any time upon sixty (60) days prior written notice to Licensee, during
the term of this Agreement and for one (1) year thereafter, to have such records examined, in its
own discretion, by an independent auditor of its own choice, provided such auditor is bound by
confidentiality in writing to Licensee and reasonably acceptable to the

 

 

Licensee. The auditor shall not disclose the contents of the examination to any other entity and
shall use the information only to verify proper reporting and payment of royalties under this
Agreement.

6.2 Once Licensee’s royalty obligations have exceeded the sums paid under Subsections 5.1(a) and
(b) above or in the event of a completed initial public offering of Licensee’s common stock, then
Licensee agrees to deliver to Licensor within forty-five (45) days of the end of each subsequent
calendar quarter a confidential written report, in a format to be agreed by the parties and made an
exhibit to this Agreement, of all Products sold by it during such quarter in sufficient detail to
permit a calculation of the royalties due thereon. Licensor shall not disclose the contents of the
report to any other entity and shall use the information only to verify proper reporting and
payment of royalties under this Agreement. Such report shall include, but not be limited to,
information of the total quantities of Products sold and the Net Sales thereof on a country by
country basis, and the amount of royalties due.

ARTICLE 7 TERM AND TERMINATION

7.1 Unless otherwise terminated as provided for in this Agreement, the license shall run to the
end of the life of the last to expire of the Patents.

7.2 The Licensee shall have the right to terminate this Agreement and surrender the license
granted hereunder at any time by giving thirty (30) days’ written notice to Licensor.

7.3 If Licensor or the Licensee is in default in the performance of any of its respective
obligations under this Agreement, including the failure by the Licensee to make any of the payments
provided for at the times specified herein, and such default is not cured within ninety (90) days
after the aggrieved party has given to the other a written notice specifying the nature of the
default, the aggrieved party shall have the right to terminate this Agreement by giving written
notice of termination to the other, subject to the remainder of this section. Upon the giving of
such notice this Agreement shall terminate; provided, however, that if there is a dispute as to the
alleged default (including as to whether there is a default, or whether it has been cured), the
aggrieved party alleging the default shall not be entitled to terminate unless and until a further
notice of termination after (i) an agreed dispute resolution entity has determined that there was a
default, as specified in the aggrieved party’s notice of default, that was not cured within the
applicable cure period and (ii) the defaulting party does not cure the default within thirty (30)
days after such determination.

7.4 If during the term of this Agreement, Licensee effects a Competitor Assignment (as defined in
Section 9.1), or a change of control over Licensee takes place meaning that fifty percent (50%) or
more of the shares in Licensee come under common control of a third party Competitor of Licensor or
Affiliates of such Competitor of Licensor, or if Licensee and/or certain of its shareholders enter
into an arrangement of a similar effect, Licensor shall be entitled to terminate this Agreement on
sixty (60) days prior written notice to Licensee. Upon such termination by Licensor, Licensor shall
promptly refund to Licensee (or its successor) a

 

 

pro rata (on a day for day basis) the annual payment made by Licensee for that year
under Section 5.1(a), 5.1(b), or 5.2, as applicable.

7.5 If during the term of this Agreement, the Licensee becomes bankrupt or insolvent, or if the
business of Licensor or the Licensee is placed in the hands of a receiver or trustee, whether by
voluntary act or otherwise, this Agreement shall immediately and automatically terminate.

7.6 The following rights and obligations shall survive any termination to the degree necessary to
permit their complete fulfilment or discharge:

	 	(a)	 	the Licensee’s obligation to supply a final report on each impacted Product in accordance
with Section 6.2 above with respect to the terminated license;
	 
	 	(b)	 	Licensor’s right to receive or recover and the Licensee’s obligation to pay royalties,
including minimum royalties, if any, accrued or accruable for payment at the time of any
termination;
	 
	 	(c)	 	the Licensee’s obligation to maintain records and to allow Licensor to audit such records
as provided for herein.

ARTICLE 8 RESTRICTED WARRANTY AND INDEMNITY

8.1 The Licensor represents and warrants that it has full authority to enter into this
Agreement, that it has not granted, and will not grant, any rights or licenses that would conflict
with the rights and licenses granted in this Agreement, that it is not aware of any third party
claims with respect to any Patent, and that it has no knowledge of any third party rights that
would affect its ability to grant the license hereunder. Licensor further represents and warrants
that the Patents are the only patent filings owned or controlled by Licensor or its Affiliates, or
which Licensor or its Affiliates otherwise have the right to enforce, license or sublicense, which
pertain to microfluidics based on multilayer soft lithography or its uses. However, the Licensor
makes no representation or warranty, express or implied, as to the validity of the Patents nor to
the merchantability or satisfactory quality of the Products that are or may be sold by the
Licensee. Licensor does not assume any liability for any infringement or alleged infringement of
any patent or other rights of third parties due to the Licensee’s activities under the license set
forth herein.

8.2 The Licensee shall assume full responsibility for its use of the Patents and shall defend
Licensor and its officers, directors, agents, and employees (“Indemnified Parties”) against any
claims or actions arising out of this Agreement by reason of death, personal injury, illness or
property damage, or any other injury or damage arising out of the use by the Licensee of the
Patents or the preparation of, use or sale of Products, including but not limited to, use or
reliance upon such Products by the Licensee’s customers, and Licensee shall indemnify the
Indemnified Parties against all liability, costs, damages, and expenses awarded against the
Indemnified Parties with respect to such claims or actions.

 

 

ARTICLE 9 MISCELLANEOUS

9.1 Assignment. This Agreement is personal to the Licensee who shall not have any right
to assign or transfer the Agreement, in whole or in part, or the license granted hereunder, without
the prior written consent of Licensor, which shall not be unreasonably withheld; provided, however,
that Licensee may transfer or assign its rights and obligations under this Agreement to a successor
to all or substantially all of Licensee’s Product business relating to one or more Licensed Fields
of Use, whether
by sale, merger or otherwise, provided further that that Licensee shall not have the right to
transfer or assign this Agreement to a Competitor of Licensor (“Competitor Assignment”) without the
prior written consent of Licensor . Notwithstanding the foregoing, Licensor shall have the right to
assign or transfer this Agreement, in whole or in part, to any Affiliate.

9.2 Entire Agreement. This Agreement constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations, representations, agreements
and understandings are merged into, extinguished by and completely expressed by it. This Agreement
may be modified or amended only by a writing executed by authorized officers of each of the
parties.

9.3 Waiver. The waiver by either Licensor or the Licensee of any right or failure to
perform or of any breach by the other shall not be deemed as a waiver of any other right hereunder
or of any other breach or failure by the other, whether of a similar nature or otherwise.

9.4 Notices. Any notice or other communication relating to this Agreement shall be sent
registered mail or overnight express prepaid or telefax/telecopier to the address of the party to
be served therewith which is shown below and shall be deemed to have been given upon the date the
notice or communication was sent:

	 	 	 	 	 
	If to Licensor:

	 	Gyros AB
	 	Att: Maris Hartmanis
	 

	 	 	 	President & CEO
	 

	 	 	 	Uppsala Science Park
	 

	 	 	 	S-751 83 Uppsala, Sweden
	 
	 	 	 	 
	 

	 	 	 	Telefax:  +46 (18) 56 6350
	 
	 	 	 	 
	with a copy to:

	 	rambe legal consultants
	 	Att: Lars J. Rambe, LL.M
	 
	 	 	 	 
	 

	 	 	 	Telefax +46-8-6508835
	 
	 	 	 	 
	If to the Licensee:

	 	Fluidigm Corporation	 	 

 

 

	 	 	 	 	 
	 

	 	 	 	Att: Gajus Worthington
	 

	 	 	 	President & CEO
	 

	 	 	 	7100 Shoreline Court
	 

	 	 	 	South San Francisco
	 

	 	 	 	CA 94080
	 
	 	 	 	 
	 

	 	 	 	Telefax: (650) 871-7152
	 
	 	 	 	 
	with a copy to:

	 	Fluidigm General Counsel
	 	Att: William M. Smith
	 
	 	 	 	 
	 

	 	 	 	Telefax: (650) 871-7195

Such addresses may be changed by notice so given.

9.5 Severability. If any provision of this Agreement is held to be unenforceable for any
reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the
parties to the extent possible. In any event, all other provisions of this Agreement shall be
deemed valid and enforceable to the full extent possible consistent with the intent of the parties.

9.6 Governing Law. This Agreement and its effects shall be subject to and shall be
construed and enforced in accordance with the laws of the state of New York, U.S.A.

9.7 Disputes. Any dispute in connection with this Agreement shall be first elevated to
each party’s respective President for a period of thirty (30) days prior to giving a notice of
default under section 9.3 above, who shall convene a face-to-face meeting prior to pursuing any
legal courses of action.

IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives
to execute this Agreement the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	Gyros AB	 	 	 	Fluidigm Corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Maris Hartmanis
	 	 	 	By:
	 	/s/ Gajus Worthington	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Maris Hartmanis
	 	 	 	 	 	Gajus Worthington	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ (ILLEGIBLE)
	 	 	 	By:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 

 

 

Exhibit A

Patent family:

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]